SIGN UP TODAY!  for latest SNPX news

Offering hope for millions of people suffering from life-threatening and debilitating diseases.


The TD Ameritrade Network interview with Dr. Daniel Alkon 


Synaptogenix (SNPX) is a clinical-stage biotech company developing targeted, novel regenerative therapeutics for neurodegenerative diseases and developmental disorders – including Alzheimer’s disease (AD).

Currently, no cure exists for Alzheimer’s and MILLIONS of people suffering from it and their loved ones are desperate for ANY treatment that may help them…

SNPX’s leading therapeutic candidate Bryostatin-1 is making promising strides to not only slow the progression of Alzheimer’s but to stop it all together and even REVERSE its effects.


Bryostatin-1 is currently in FDA Phase 2b trials for its treatment of AD.

The goal of Bryostatin-1 is to repair damaged synapses in the brain, as synapse loss has been shown to be the strongest correlate for cognitive decline in AD.
Promising results have been found so far in preclinical studies of AD transgenic mice – such that Bryostatin-1 RESTORED synaptic connections, resulting in an ABOVE baseline improvement for patients with advanced Alzheimer’s Disease.

These positive effects were persistent for at least one month after dosing.


SNPX expects to announce topline data from its Alzheimer’s Phase 2b trial during the fourth quarter of 2022 – data that could affect the lives of millions of people in a positive way.

To summarize the restorative potential of Bryostatin-1, here are before and after images of regenerated synapses in the brain provided by Dr. Daniel Alkon (source). 

Treated Without Bryostatin

Treated With Bryostatin

Beyond Alzheimer’s, the company’s experience and passion for novel drug therapies have led to a pipeline that includes synaptogenic treatment approaches for other serious and difficult-to-treat diseases such as Fragile X Syndrome, MS, Parkinsons, Traumatic Brain Injury, Stroke and Autism Spectrum Disorders.

SNPX has received substantial financial support to pursue its work, including over $200 million from the Blanchette Rockefeller Neurosciences Institute and the National Institutes of Health (NIH).

Executive Team

Synaptogenix is led by an experienced team with deep expertise in neurodegenerative disorders and successful track records in both drug discovery and development.

Alan Tuchman, M.D.

Alan Tuchman, M.D.

Chief Executive Officer

Robert Weinstein

Robert Weinstein

Chief Financial Officer

Daniel Alkon, M.D.

Daniel Alkon, M.D.

President & Chief Science Officer

Elaine Grenier

Elaine Grenier

Executive Director, Clinical Ops

FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, neither Sherwood Ventures, LLC (“Sherwood”) nor, LLC (“Raging Bull”) can guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision.
SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments.
NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither Sherwood nor Raging Bull, or any of their owners, employees or independent contractors is currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.
USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at
TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied.
ISSUER-PAID ADVERTISEMENT. Synaptogenix, Inc. (“SNPX” or the “Company”) has paid or will pay Sherwood $30,000 USD per month for three months (the “Initial Term”) in cash, shares of restricted common stock with a value of $150,000, and warrants valued at issuance of $75,000 for marketing services including communicating to the public about the company through Sherwood’s affiliate Raging Bull, among others. This advertisement is part of those issuer-paid marketing services. The contract with SNPX automatically renews for successive one-month periods following the Initial Term (the “Renewal Term”) unless it is terminated by written notice of either party prior to the end of the previous term. During the Renewal Term, SNPX has agreed to pay Sherwood a monthly fee of $30,000 in cash, shares of restricted stock with a value of $50,000 and warrants valued at $25,000. As a result of this advertisement and other marketing efforts, Sherwood and/or Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, Sherwood and Raging Bull, and any of their respective officers, principals, or affiliates (as defined in the Securities Act of 1933, as amended, and Rule 501(b) promulgated thereunder) hold the securities of SNPX and, as permitted by law, may sell those shares during the course of this marketing arrangement or afterwards. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of SNPX, increased trading volume, and possibly an increased share price of the SNPX’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended.

For The NEWEST And HOTTEST Information On Startup Sectors, Publicly Traded Companies And All Things Private Equity Has To Offer, Join Boardroom’s Investing Community By Entering Your Email Address HERE